Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma

Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12.

Abstract

Introduction: The role of the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade demonstrated spectacular efficacy in relapsed/refractory disease. However, little is known about the frequency and cellular distribution of other immune checkpoints in HL samples.

Patients and methods: Using immunohistochemistry, we investigated, along with PD-L1 and PD-1, the expression of lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) in 57 biopsy samples of patients with classical HL.

Results: Hodgkin and Reed/Sternberg (HRS) cells were strongly positive for PD-L1 in nearly all cases. HRS cells were TIM-3 positive in 36% of samples, whereas LAG-3 was rarely expressed (5.2%). In the microenvironment, PD-1, LAG-3, and TIM-3 were expressed by ≥ 5% of cells in 65%, 98%, and 96% of cases, respectively. T-cell rosettes surrounding HRS cells consisted of CD4+ FoxP3- helper T cells expressing both PD-1 and LAG-3, with a variable expression of TIM-3.

Conclusion: This study demonstrates for the first time that LAG-3 and TIM-3 are nearly always expressed in the microenvironment of classical HL. This may constitute the basis for targeting LAG-3 or TIM-3 in combination with anti-PD-1 antibodies in the treatment of relapsed/refractory HL.

Trial registration: ClinicalTrials.gov NCT02061761 NCT03446040.

Keywords: Hodgkin and Reed/Sternberg cells; Immune checkpoints; Immunohistochemistry; Multiplex immunofluorescence; Tumor microenvironment.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / analysis
  • Antigens, CD / genetics*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • B7-H1 Antigen / analysis
  • B7-H1 Antigen / genetics
  • Biopsy
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Hepatitis A Virus Cellular Receptor 2 / analysis
  • Hepatitis A Virus Cellular Receptor 2 / antagonists & inhibitors
  • Hepatitis A Virus Cellular Receptor 2 / genetics*
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / genetics*
  • Hodgkin Disease / pathology
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lymphocyte Activation Gene 3 Protein
  • Male
  • Middle Aged
  • Programmed Cell Death 1 Receptor / analysis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / genetics
  • Reed-Sternberg Cells / pathology
  • Tumor Microenvironment / genetics
  • Tumor Microenvironment / immunology
  • Young Adult

Substances

  • Antigens, CD
  • B7-H1 Antigen
  • CD274 protein, human
  • HAVCR2 protein, human
  • Hepatitis A Virus Cellular Receptor 2
  • Immune Checkpoint Inhibitors
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Lymphocyte Activation Gene 3 Protein
  • Lag3 protein, human

Associated data

  • ClinicalTrials.gov/NCT02061761
  • ClinicalTrials.gov/NCT03446040